Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1987 1
2007 1
2008 1
2009 1
2010 1
2011 4
2013 1
2014 1
2016 2
2017 2
2018 8
2019 4
2020 7
2021 9
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, Vogl U, Rekowski J, Rouhifard M, Gallagher L, Yuan W, Carreira S, Chandran K, Paschalis A, Colombo I, Stathis A, Bertan C, Seed G, Goodall J, Raynaud F, Ruddle R, Swales KE, Malia J, Bogdan D, Tiu C, Caldwell R, Aversa C, Ferreira A, Neeb A, Tunariu N, Westaby D, Carmichael J, Fenor de la Maza MD, Yap C, Matthews R, Badham H, Prout T, Turner A, Parmar M, Tovey H, Riisnaes R, Flohr P, Gil J, Waugh D, Decordova S, Schlag A, Calì B, Alimonti A, de Bono JS. Guo C, et al. Among authors: paschalis a. Nature. 2023 Nov;623(7989):1053-1061. doi: 10.1038/s41586-023-06696-z. Epub 2023 Oct 16. Nature. 2023. PMID: 37844613 Free PMC article.
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil V, Miranda S, Riisnaes R, Gurel B, D'Ambrosio M, Vasciaveo A, Crespo M, Ferreira A, Brina D, Troiani M, Sharp A, Sheehan B, Christova R, Seed G, Figueiredo I, Lambros M, Dolling D, Rekowski J, Alajati A, Clarke M, Pereira R, Flohr P, Fowler G, Boysen G, Sumanasuriya S, Bianchini D, Rescigno P, Aversa C, Tunariu N, Guo C, Paschalis A, Bertan C, Buroni L, Ning J, Carreira S, Workman P, Swain A, Califano A, Shen MM, Alimonti A, Neeb A, Welti J, Yuan W, de Bono J; PCF/SU2C International Prostate Cancer Dream Team. Gil V, et al. Among authors: paschalis a. Cancer Res. 2021 Dec 15;81(24):6207-6218. doi: 10.1158/0008-5472.CAN-21-3360. Epub 2021 Nov 9. Cancer Res. 2021. PMID: 34753775 Free PMC article.
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS. Carreira S, et al. Among authors: paschalis a. Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27. Cancer Discov. 2021. PMID: 34045297 Free PMC article. Clinical Trial.
Critical role of antioxidant programs in enzalutamide-resistant prostate cancer.
Blatt EB, Parra K, Neeb A, Buroni L, Bogdan D, Yuan W, Gao Y, Gilbreath C, Paschalis A, Carreira S, DeBerardinis RJ, Mani RS, de Bono JS, Raj GV. Blatt EB, et al. Among authors: paschalis a. Oncogene. 2023 Jul;42(30):2347-2359. doi: 10.1038/s41388-023-02756-w. Epub 2023 Jun 24. Oncogene. 2023. PMID: 37355762 Free PMC article.
Alternative splicing in prostate cancer.
Paschalis A, Sharp A, Welti JC, Neeb A, Raj GV, Luo J, Plymate SR, de Bono JS. Paschalis A, et al. Nat Rev Clin Oncol. 2018 Nov;15(11):663-675. doi: 10.1038/s41571-018-0085-0. Nat Rev Clin Oncol. 2018. PMID: 30135575 Review.
Characterizing CDK12-Mutated Prostate Cancers.
Rescigno P, Gurel B, Pereira R, Crespo M, Rekowski J, Rediti M, Barrero M, Mateo J, Bianchini D, Messina C, Fenor de la Maza MD, Chandran K, Carmichael J, Guo C, Paschalis A, Sharp A, Seed G, Figueiredo I, Lambros M, Miranda S, Ferreira A, Bertan C, Riisnaes R, Porta N, Yuan W, Carreira S, de Bono JS. Rescigno P, et al. Among authors: paschalis a. Clin Cancer Res. 2021 Jan 15;27(2):566-574. doi: 10.1158/1078-0432.CCR-20-2371. Epub 2020 Sep 28. Clin Cancer Res. 2021. PMID: 32988971 Free PMC article.
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer.
Westaby D, Fenor de La Maza MLD, Paschalis A, Jimenez-Vacas JM, Welti J, de Bono J, Sharp A. Westaby D, et al. Among authors: paschalis a. Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:131-153. doi: 10.1146/annurev-pharmtox-052220-015912. Epub 2021 Aug 24. Annu Rev Pharmacol Toxicol. 2022. PMID: 34449248 Review.
Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker.
Birmpilis AI, Paschalis A, Mourkakis A, Christodoulou P, Kostopoulos IV, Antimissari E, Terzoudi G, Georgakilas AG, Armpilia C, Papageorgis P, Kastritis E, Terpos E, Dimopoulos MA, Kalbacher H, Livaniou E, Christodoulou MI, Tsitsilonis OE. Birmpilis AI, et al. Among authors: paschalis a. Cells. 2022 Apr 22;11(9):1415. doi: 10.3390/cells11091415. Cells. 2022. PMID: 35563721 Free PMC article. Review.
Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.
Sheehan B, Neeb A, Buroni L, Paschalis A, Riisnaes R, Gurel B, Gil V, Miranda S, Crespo M, Guo C, Jiménez Vacas J, Figueiredo I, Ferreira A, Welti J, Yuan W, Carreira S, Sharp A, de Bono J. Sheehan B, et al. Among authors: paschalis a. Clin Cancer Res. 2022 Jul 15;28(14):3104-3115. doi: 10.1158/1078-0432.CCR-21-4531. Clin Cancer Res. 2022. PMID: 35552383 Free PMC article.
46 results